Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Vor Biopharma ( (VOR) ) is now available.
On March 26, 2026, Vor Biopharma Inc. entered into a securities purchase agreement with healthcare investment firm TCGX for a $75 million private placement of 5,338,078 common shares at $14.05 per share, with closing expected around March 30, 2026. The deal, which will leave Vor with about 54.2 million shares outstanding, was executed without a placement agent and relies on a private offering exemption from U.S. securities registration.
Vor plans to use the proceeds to advance clinical development of telitacicept, including ongoing global Phase 3 trials in generalized myasthenia gravis and primary Sjögren’s disease, as well as for business development and general corporate purposes. A concurrent registration rights agreement commits the company to register the resale of the new shares, underscoring efforts to secure long-term capital support for its autoimmune pipeline and strengthen its position in BAFF/APRIL-targeted therapies.
The most recent analyst rating on (VOR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, heavy cash burn, and a sharp deterioration to deeply negative equity). Offsetting this are improving near-term technical momentum and positive corporate developments (recent financings and encouraging telitacicept updates), but valuation remains constrained by ongoing losses and no dividend support.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases. It is centered on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 development and potential commercialization to address serious autoantibody-driven conditions worldwide.
Average Trading Volume: 918,052
Technical Sentiment Signal: Sell
Current Market Cap: $563.4M
See more data about VOR stock on TipRanks’ Stock Analysis page.